# Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

> **NCT04183192** · PHASE1 · COMPLETED · sponsor: **Food and Drug Administration (FDA)** · enrollment: 72 (actual)

## Conditions studied

- Healthy Subjects
- Pharmacokinetics
- Pharmacodynamics

## Interventions

- **BIOLOGICAL:** Mepolizumab
- **BIOLOGICAL:** Mepolizumab
- **BIOLOGICAL:** Mepolizumab
- **BIOLOGICAL:** Mepolizumab
- **BIOLOGICAL:** Reslizumab
- **BIOLOGICAL:** Reslizumab
- **BIOLOGICAL:** Reslizumab
- **BIOLOGICAL:** Reslizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04183192
- **Lead sponsor:** Food and Drug Administration (FDA)
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-17
- **Primary completion:** 2021-04-04
- **Final completion:** 2021-04-04
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183192, "Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04183192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*